Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
about
Crizotinib: from discovery to accelerated development to front-line treatmentTargeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationCIViC databaseActivity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Ceritinib: A primer for pharmacists.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatmentNovel agents in development for advanced non-small cell lung cancer.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsAlectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases.Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Metachronous primary uterine cancer surgically resected during Crizotinib treatment in a ALK-rearranged advanced lung adenocarcinoma.Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsThe Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer.Update on systemic therapy of advanced non-small-cell lung cancer.Management of NSCLC: focus on crizotinib.New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.Alectinib for treatment of ALK-positive non-small-cell lung cancer.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.ALK alterations and inhibition in lung cancer.
P2860
Q26738385-C19C9A44-26CD-4080-BB08-AC3A10D93D4BQ26738986-1792431D-A289-44CD-B883-C7FE11850D33Q26740329-77C4085D-EE14-44F4-81D4-76104A635427Q26745427-1AD46071-A4D8-4019-9D0B-806A0F68EBECQ26777486-9902C480-ED20-4FBE-8F6E-CC3262FF2521Q26795555-3BF482A5-F27C-46FF-B705-7B95C05467A1Q26795556-0BD52123-1B65-4195-8DF3-56C4E0DD1E36Q27612411-C11F04C8-1074-45C8-890A-0967837C334DQ27853360-5BFFA781-C9E0-4414-952D-BCAC90357F29Q30244613-5BCC6C69-7E84-4A99-B312-72E246D70138Q33567889-C2992B9C-7EA6-4C5C-B791-D7407065D799Q33591738-522B9DEE-F57E-4A34-8F64-BADE5FE62749Q34127899-36B6DE77-5B04-448B-B012-14F7EF7A07E6Q34389263-D23165C4-4F8C-46F3-BB59-55CDB996AA7AQ34564071-25018490-1C96-47D4-B706-060FE2938A58Q35057308-800EC31E-40E7-42D6-9EC3-853764726B52Q35549714-1333D55F-5952-4F3E-BBA3-81CDA90F8935Q35909271-62B7F346-8253-4C71-BA06-08117AB82C98Q35918612-D3EAE7CB-C3BE-4364-A094-0E895C57951BQ36322851-9C477F0F-7E84-4280-BA2F-846AE432E727Q36594257-78DCA247-73ED-45A5-9606-FA8D51E8B2FBQ36797256-DF8C70EC-7867-479B-BCA5-0816F2B7C417Q37045504-B9F7E677-36DC-4061-ADAF-B0F8CD664F7CQ37350770-7BF44A1C-02E6-4A52-AAEF-3981E94B1715Q37462477-AC155B1F-1167-409C-B28F-7219C3E09282Q37649196-2F306971-D590-46C8-B3AE-5FDB482FB86EQ37662206-98B8E769-6CF1-4E20-835C-268BC99BA9BCQ37737536-685C2BDE-7CC7-4904-9797-17C9D27019B2Q38237463-1D65065F-CB7A-487F-85CA-EFF0239827C3Q38258633-8575C52A-A37C-4D4A-86C7-BF8ADA50ED32Q38576015-8C2636B5-72C3-47EB-8469-A8C284192A7BQ38631019-10BA2226-864A-4FBD-A53A-1C3B64A99D64Q38669285-33DC933D-2954-4F48-BF6A-8CD61E36478CQ38739807-579710E3-39D5-430B-908A-839A9C854954Q38746336-C6127E35-CF37-4F6C-9F7E-D7CF1943C68FQ38748356-E138C61C-74F1-4344-A0C0-59F2C1FCBB74Q38763108-E2183FE8-A534-41AA-9E67-359DB8BF66EDQ38805618-9A688814-23CA-4797-A558-66F265A2C865Q38816700-575D91B2-6704-40FB-A03F-E101539FA838Q38820412-8406544E-4AEC-43E7-9F06-78A0A1A083A8
P2860
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@ast
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@en
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@nl
type
label
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@ast
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@en
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@nl
prefLabel
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@ast
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@en
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@nl
P2093
P2860
P3181
P356
P1433
P1476
Clinical benefit of continuing ...... h advanced ALK-positive NSCLC.
@en
P2093
C H Bartlett
G A Otterson
P2860
P304
P3181
P356
10.1093/ANNONC/MDT572
P577
2014-02-01T00:00:00Z